In Central Obesity, Weight Loss Restores Platelet Sensitivity to Nitric Oxide and Prostacyclin
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Central obesity shows impaired platelet responses to the antiaggregating effects of nitric oxide (NO), prostacyclin, and their effectors—guanosine 3′,5′‐cyclic monophosphate (cGMP) and adenosine 3′,5′‐cyclic monophosphate (cAMP). The influence of weight loss on these alterations is not known. To evaluate whether a diet‐induced body‐weight reduction restores platelet sensitivity to the physiological antiaggregating agents and reduces platelet activation in subjects affected by central obesity, we studied 20 centrally obese subjects before and after a 6‐month diet intervention aiming at reducing body weight by 10%, by measuring (i) insulin sensitivity (homeostasis model assessment of insulin resistance (HOMA IR)); (ii) plasma lipids; (iii) circulating markers of inflammation of adipose tissue and endothelial dysfunction, and of platelet activation (i.e., soluble CD‐40 ligand (sCD‐40L) and soluble P‐selectin (sP‐selectin)); (iv) ability of the NO donor sodium nitroprusside (SNP), the prostacyclin analog Iloprost and the cyclic nucleotide analogs 8‐bromoguanosine 3′,5′‐cyclic monophosphate (8‐Br‐cGMP) and 8‐bromoadenosine 3′,5′‐cyclic monophosphate (8‐Br‐cAMP) to reduce platelet aggregation in response to adenosine‐5‐diphosphate (ADP); and (v) ability of SNP and Iloprost to increase cGMP and cAMP. The 10 subjects who reached the body‐weight target showed significant reductions of insulin resistance, adipose tissue, endothelial dysfunction, and platelet activation, and a significant increase of the ability of SNP, Iloprost, 8‐Br‐cGMP, and 8‐Br‐cAMP to reduce ADP‐induced platelet aggregation and of the ability of SNP and Iloprost to increase cyclic nucleotide concentrations. No change was observed in the 10 subjects who did not reach the body‐weight target. Changes of platelet function correlated with changes of HOMA IR. Thus, in central obesity, diet‐induced weight loss reduces platelet activation and restores the sensitivity to the physiological antiaggregating agents, with a correlation with improvements in insulin sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 2×
“Actually, abdominal fat deposition is characterized by a greater ability to release cytokines and free fatty acids than subcutaneous fat deposition, and therefore is more deeply involved in the pathogenesis of both atherothrombosis and insulin resistance (5,6).”
BackgroundMechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 2×
“Actually, abdominal fat deposition is characterized by a greater ability to release cytokines and free fatty acids than subcutaneous fat deposition, and therefore is more deeply involved in the pathogenesis of both atherothrombosis and insulin resistance (5,6).”
BackgroundLichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176158 · Cited by 2,705
Platelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135
Esposito, K., Pontillo, A., Di Palo, C., Giugliano, G., Masella, M., Marfella, R., & Giugliano, D. (2003) · JAMA · doi:10.1001/jama.289.14.1799 · Cited by 1,511 · cited 2×
“Furthermore, the study shows for the first time that a modest weight loss obtained by a diet intervention corrects not only insulin resistance, subclinical inflammation, adipose tissue, and endothelial dysfunction—as already described (24,25)— but also peculiar aspects of platelet dysfunction.”
BackgroundDandona, P., Aljada, A., Chaudhuri, A., Mohanty, P., & Garg, R. (2005) · Circulation · doi:10.1161/01.cir.0000158483.13093.9d · Cited by 1,263 · cited 2×
“In conclusion, this study suggests that platelet dysfunction should be added to the wide list of vascular abnormalities linked to the reduced insulin action (34,35) and clearly shows that a diet-induced body-weight reduction >10% restores platelet function by improving insulin sensitivity.”
BackgroundStevens, V. J., Obarzanek, E., Cook, N. R., Lee, I.-M., Appel, L. J., Smith West, D., Milas, N. C., Mattfeldt-Beman, M., Belden, L., Bragg, C., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-1-200101020-00007 · Cited by 886 · cited 1×
“It has been observed that intentional weight loss reduces total mortality and cardiovascular events (21), likely through a beneficial influence on lipids, such as high-density lipoprotein (HDL) cholesterol and triglycerides (22), blood pressure (23), endothelial dysfunction (24), low-grade inflammation (25), and type…”
Background
Cited by
Kaur, R., Kaur, M., & Singh, J. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0763-3 · Cited by 736
Inflammation, obesity, and thrombosis
Samad, F., & Ruf, W. (2013) · Blood · doi:10.1182/blood-2013-05-427708 · Cited by 414
Novel roles of cAMP/cGMP‐dependent signaling in platelets
SMOLENSKI, A. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04576.x · Cited by 312
Platelet activation in obesity and metabolic syndrome
Santilli, F., Vazzana, N., Liani, R., Guagnano, M. T., & Davì, G. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00930.x · Cited by 258
Diabetes mellitus and thrombosis
Vazzana, N., Ranalli, P., Cuccurullo, C., & Davì, G. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2011.11.052 · Cited by 257
New insights into the role of adipose tissue in thrombosis
Vilahur, G., Ben-Aicha, S., & Badimon, L. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx086 · Cited by 216
Kahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., Ajjan, R. A., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0005-6 · Cited by 74
“Our findings are important as the majority of previous reports suggest the need for moderate weight loss (≥10%) to achieve reduction in atherothrombotic risk [9,27].”
BackgroundInfluentialZheng, Z., Nakamura, K., Gershbaum, S., Wang, X., Thomas, S., Bessler, M., Schrope, B., Krikhely, A., Liu, R.-M., Ozcan, L., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135919 · Cited by 43
Metadata
- Authors
- Russo, I., Traversa, M., Bonomo, K., De Salve, A., Mattiello, L., Del Mese, P., Doronzo, G., Cavalot, F., Trovati, M., & Anfossi, G.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2010-04
- Volume
- 18
- Issue
- 4
- Pages
- 788-797
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W1975968925
- Cited by
- 76
- References
- 16
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.